Connor Clark & Lunn Investment Management Ltd. lessened its stake in HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 47.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,384 shares of the company's stock after selling 51,778 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.07% of HealthEquity worth $5,506,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Holocene Advisors LP purchased a new position in HealthEquity in the 3rd quarter worth approximately $1,246,000. GSA Capital Partners LLP purchased a new stake in shares of HealthEquity in the 3rd quarter valued at $638,000. Natixis Advisors LLC boosted its stake in shares of HealthEquity by 29.8% in the 3rd quarter. Natixis Advisors LLC now owns 209,175 shares of the company's stock valued at $17,122,000 after purchasing an additional 48,009 shares in the last quarter. Vaughan Nelson Investment Management L.P. boosted its stake in shares of HealthEquity by 36.7% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 843,423 shares of the company's stock valued at $69,034,000 after purchasing an additional 226,563 shares in the last quarter. Finally, Loomis Sayles & Co. L P boosted its stake in shares of HealthEquity by 2.2% in the 3rd quarter. Loomis Sayles & Co. L P now owns 1,126,645 shares of the company's stock valued at $92,216,000 after purchasing an additional 24,665 shares in the last quarter. Hedge funds and other institutional investors own 99.55% of the company's stock.
Wall Street Analysts Forecast Growth
HQY has been the subject of a number of research reports. Mizuho initiated coverage on shares of HealthEquity in a research note on Wednesday, December 4th. They issued an "outperform" rating and a $126.00 price objective for the company. JMP Securities upped their price objective on shares of HealthEquity from $105.00 to $107.00 and gave the stock a "market outperform" rating in a report on Tuesday, December 10th. Wells Fargo & Company increased their price target on shares of HealthEquity from $110.00 to $125.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Royal Bank of Canada increased their price target on shares of HealthEquity from $100.00 to $105.00 and gave the stock an "outperform" rating in a research note on Tuesday, December 10th. Finally, Raymond James increased their price target on shares of HealthEquity from $105.00 to $120.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 25th. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $112.92.
Check Out Our Latest Stock Report on HealthEquity
Insider Buying and Selling at HealthEquity
In other news, Director Robert W. Selander sold 5,750 shares of the firm's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $111.29, for a total transaction of $639,917.50. Following the completion of the transaction, the director now owns 78,219 shares in the company, valued at $8,704,992.51. This trade represents a 6.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 2.20% of the company's stock.
HealthEquity Stock Performance
HealthEquity stock traded up $0.28 during trading on Thursday, reaching $84.60. The company had a trading volume of 2,370,576 shares, compared to its average volume of 918,222. HealthEquity, Inc. has a 52 week low of $65.01 and a 52 week high of $115.59. The firm's 50-day simple moving average is $105.51 and its 200 day simple moving average is $95.59. The firm has a market capitalization of $7.33 billion, a price-to-earnings ratio of 77.61, a price-to-earnings-growth ratio of 1.60 and a beta of 0.62. The company has a current ratio of 3.20, a quick ratio of 3.20 and a debt-to-equity ratio of 0.51.
HealthEquity Company Profile
(
Free Report)
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Read More
Before you consider HealthEquity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.
While HealthEquity currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
